Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab

KRAS mutation is a predictive biomarker for resistance to cetuximab (Erbitux®) in metastatic colorectal cancer (mCRC). This study sought to determine if KRAS mutant CRC lines could be sensitized to cetuximab using dasatinib (BMS-354825, sprycel®) a potent, orally bioavailable inhibitor of several ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunn, Emily F., Iida, Mari, Myers, Rebecca A., Hintz, Kylee A., Campbell, David A., Armstrong, Eric A., Li, Chunrong, Wheeler, Deric L.
Formato: Texto
Lenguaje:English
Publicado: 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025039/
https://www.ncbi.nlm.nih.gov/pubmed/20956938
http://dx.doi.org/10.1038/onc.2010.430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025039/
https://www.ncbi.nlm.nih.gov/pubmed/20956938
http://dx.doi.org/10.1038/onc.2010.430

Ejemplares similares